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LETTERS TO THE EDITOR
Long-Standing Debate
on Cisplatin- Versus
Carboplatin-Based
Chemotherapy in the
Treatment of Advanced
Non-small Cell
Lung Cancer
To the Editor:
In the treatment of advanced non-
small cell lung cancer (NSCLC), cispla-
tin-based chemotherapy has a significant
impact on survival, as reported in a large
meta-analysis.1 The standard chemo-
therapy regimen is a doublet of cisplatin
plus one of the new agents.2 However,
cisplatin traditionally has serious toxic-
ities, which have prompted a worldwide
search for cisplatin analogues with a
better therapeutic index. Among them,
only carboplatin fulfilled all require-
ments for marketing approval; its neph-
rotoxicity, neuropathy, and gastrointes-
tinal toxicities were milder than those
of cisplatin.3 To date, there are eight
randomized trials addressing the issue
of cisplatin/carboplatin combined with
other cytotoxic agents. However, the re-
sults of these trials are conflicting; cis-
platin-based chemotherapy was superior
to carboplatin-based chemotherapy in
terms of survival in several trials,
whereas the other showed a significant
survival advantage of carboplatin-based
chemotherapy. Thus, the choice of cis-
platin or carboplatin has been a point of
controversy and, consequently, possible
equivalency in efficacy, its superior tox-
icity profiles, and convenience of ad-
ministration led to the predominant role
of carboplatin in the marketplace for the
treatment of advanced NSCLC.
To clarify this conflicting issue,
we first conducted a meta-analysis using
abstracted data.4 The analysis revealed
that the objective response rate was
higher in those with cisplatin-based che-
motherapy but without any statistically
significant survival advantage (hazard
ratio [HR], 1.050; 95% confidence inter-
val [CI], 0.907–1.216; p  0.515). Sub-
group analysis revealed that combina-
tion chemotherapy of cisplatin-based
chemotherapy yielded a longer survival
when combined with new agents (HR,
1.106; 95%CI, 1.005–1.218; p 0.039).
More recently, an individual patient da-
ta-based meta-analysis confirmed our
data with a quite consistent result (HR,
1.07; 95%CI, 0.99–1.15; p  0.101 and
HR, 1.11; 95%CI, 1.01–1.21; p 
0.026).5 These data indicate that cispla-
tin is superior to carboplatin in terms of
overall survival, especially when com-
bined with new cytotoxic agents such as
docetaxel, paclitaxel, and gemcitabine.
What can we conclude from this
information? Is there a clinically signif-
icant difference between cisplatin-based
regimens and carboplatin-based regi-
mens? It seems that the answer should
be “yes” in terms of overall survival,
and cisplatin should remain the key
agent for patients with a good perfor-
mance status. However, the survival dif-
ference is modest. Additionally, we
should take into account other clinical
parameters; for example, toxicity pro-
files are quite different between the two
treatment strategies.4,5 Cisplatin admin-
istration also usually requires a rather
complex and time-consuming procedure
compared with carboplatin. None of
these situations should be taken to mean
that carboplatin no longer has any role in
the management of advanced diseases,
when all of this information is applied to
daily clinical practice. An appropriate
treatment strategy should be considered
at an individual patient level, taking into
consideration not only the major end
point, overall survival, but also all these
other parameters.
Finally, the outcome of patients
with metastatic NSCLC is poor, regard-
less of whether they are treated with cis-
platin- or carboplatin-based regimens.
Many clinical trials have indicated no fur-
ther improvement in treatment outcome
with the existing chemotherapeutic agents.
We still need to continue to take advan-
tage of the recent advances we have made
in the understanding of basic tumor biol-
ogy to produce better treatment options.
Katsuyuki Hotta, MD, PhD*, and
Keitaro Matsuo, MD, MSc, PhD†
*Department of Respiratory Medicine,
Okayama University Hospital, Okayama;
†Division of Epidemiology and Prevention,
Aichi Cancer Center Research Institute,
Aichi, Japan
REFERENCES
1. Non-Small Cell Lung Cancer Collaborative
Group. Chemotherapy in non-small cell lung
cancer: a meta-analysis using updated data on
individual patients from 52 randomized clini-
cal trials. BMJ 1995;311:899–909.
2. Baggstrom MQ, Socinski MA, Hensing TA,
Poole C. Third generation chemotherapy reg-
imens (3GR) improve survival over second
generation regimens (2GR) in stage IIIB/IV
non-small cell lung cancer (NSCLC): a meta-
analysis of the published literature (Abstract).
Proc Am Soc Clin Oncol 2002;21:306a.
3. Go RS, Adjei AA. Review of the comparative
pharmacology and clinical activity of cisplatin
and carboplatin. J Clin Oncol 1999;17:409–
422.
4. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata
M, Tanimoto M. Meta-analysis of randomized
clinical trials comparing cisplatin to carboplatin
in patients with advanced non-small-cell lung
cancer. J Clin Oncol 2004;22:3852–3859.
5. Ardizzoni A, Tiseo M, Boni L, et al. CISCA
(cisplatin vs. carboplatin) meta-analysis: an
individual patient data meta-analysis com-
paring cisplatin versus carboplatin-based
chemotherapy in first-line treatment of ad-
vanced non-small cell lung cancer (NSCLC)
(Abstract). Proc Am Soc Clin Oncol
2006;24:7011.
Safety Profile of
Erlotinib in Patients
with Advanced
Non-small Cell Lung
Cancer with Chronic
Renal Failure
To the Editor:
Erlotinib (OSI 774, Tarceva), an
epidermal growth factor receptor
Address for correspondence: Katsuyuki Hotta,
MD, PhD, Department of Respiratory Medi-
cine, Okayama University Hospital, 2-5-1,
Shikata-cho, Okayama, 700-8558, Japan. E-mail:
khotta@md.okayama-u.ac.jp
Copyright © 2007 by the International Association
for the Study of Lung Cancer
ISSN: 1556-0864/07/0201-0096
Address for correspondence: Dr. Cesare Gridelli,
Division of Medical Oncology, “S.G. Moscati”
Hospital, Citta` Ospedaliera, Contrada Amoretta,
83100 Avellino, Italy. E-mail: cgridelli@libero.it
Copyright © 2007 by the International Association
for the Study of Lung Cancer
ISSN: 1556-0864/07/0201-0096
Journal of Thoracic Oncology • Volume 2, Number 1, January 200796
